Your Samples Are in Good Hands With Us!
From regulatory precision to preserving sample integrity, shipments can be challenging.
Let us navigate and mitigate these challenges for you with a team of logistical experts to:
- Streamline regulatory compliance through optimized documentation practices.
- Prioritize secure, temperature-controlled shipments with reliable couriers.
- Ensure your samples maintain their integrity with temperature monitoring, robust packaging, and contingency planning.
Our tailored concierge-style sample shipping ensures your test materials reach the correct destination safely and on time.
You may also be interested in the below resources:
Fact Sheets:
Sample Kits
Bioanalytical Services
Webpages
Q&A With Dr. Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical Solutions for Your Gene Therapy Studies
Recent advances in gene therapy have allowed for diseases to be approached differently. Gene therapy was first discovered in the 1960s, but only gained commercial interest in the 1980s. It wasn’t until 1990 that the first successful gene therapy treatment on a patient transpired.
Discover the Benefits of Altasciences' Centralized Program Management
Fewer Hand-Offs for Shorter Timelines and Reduced Costs
Imagine the convenience of having a single point of contact guiding you through each step of drug development, from preclinical to early-phase clinical studies. When you partner with Altasciences, our program managers work closely with you from the get-go to understand your unique needs and objectives, and deliver tailored solutions that meet your requirements.
Our streamlined approach and efficient coordination ensure seamless integration of activities, optimizing resources and maximizing productivity.
Explore our fact sheet to discover the power of centralized program management with Altasciences.
Ready to get started? Schedule a conversation with one of our experts.
You may also be interested in these insightful resources:
• Webinar: The Path Forward, Altasciences' Approach to Project Management
• Video: The Benefits of Conducting a Clinical Trial in Canada
• Webpage: CRO Services For Clinical Research
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
Originally published by Hoth Therapeutics via PR Newswire on February 26, 2024
NEW YORK , Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
"We continue to make strides in moving HT-KIT from the lab to patients and this further analysis will help us with that process as a final step in the preclinical development that allows us to finalizing the protocols in our upcoming IND-enabling," stated Robb Knie , Chief Executive Officer. "We are pleased to further engage Altasciences on these studies given its great reputation for full-service solutions including preclinical safety testing, clinical pharmacology and bioanalysis."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer's Disease, atopic dermatitis and other indications. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia: https://www.prnewswire.com/news-releases/hoth-therapeutics-engages-altasciences-to-perform-key-study-for-ht-kit-cancer-fighting-therapeutic-302070680.html
SOURCE Hoth Therapeutics, Inc.
Achieve Enhanced API Formulation Development Using This Technique
Insoluble APIs, Meet Your Match!
Poorly soluble active pharmaceutical ingredients (APIs) made from hydrophobic, amorphous-solid, or crystalline-type materials are highly manageable when you opt for nanomilling ― a complex and game-changing process that pulverizes and stabilizes particles.
Hear more on the topic from Andrew Buis, Senior Formulation Scientist at Altasciences, in this short video.
![](https://www.altasciences.com/sites/default/files/2024-03/handling_poorly_soluble_APIs.png)
If you have any questions about nanomilling or need help formulating your APIs, speak with one of our experts today.
You may also be interested in:
• Webpage: Drug Manufacturing and Analytical Testing Services
• Scientific Journal: Achieving Better Solubility and Bioavailability
• Webinar: Development of Nanosuspension Formulations for Poorly Soluble Drugs
Intricacies of Conducting Juvenile Toxicology Studies
The Development Path to Safer Pediatric Trials
Juvenile animal toxicity studies are fundamental in gathering safety data and identifying potential negative side effects on postnatal growth and development―ones that may be missed in standard toxicity assessments. These evaluations also provide crucial safety data required to carry out pediatric clinical trials with young patients, particularly in cases where toxicities that are difficult to assess in humans are a concern.
Our experts can advise on and design the best testing strategy for juvenile toxicity studies. Watch this educational video for guidance on:
• choosing the appropriate animal model for these types of studies;
• the role of miniature swine in juvenile toxicity studies; and
• insights on study designs and endpoints.
For help with your specific juvenile toxicology studies, speak with one of our experts.
Healing Hearts: A Journey of Compassion and Commitment
GETTING TO THE HEART OF SCIENCE WITH MARTA RODRIGUEZ
![Marta Rodriguez, Director of Clinical Operations at Altasciences](/sites/default/files/inline-images/Marta%20Rodriguez%20%282%29_preferred_500x500px.jpg)
At the heart of science are stories—stories of expe
A Deep Dive Into the FDA's Psychedelic Clinical Research Guidelines
Decoding FDA Requirements
Watch as Altasciences’ panel of experts discuss the FDA’s recently published guidelines for early-phase clinical development of psychedelics and the assessment of abuse potential.
Topics covered:
• important FDA recommendations;
• clinical methods to optimize early-phase clinical trials with psychedelics;
• how to address the abuse potential evaluation requirement for psychedelic drugs; and
• strategies to ensure study integrity.
You may also be interested in the following resources:
• Webpage: CNS Drug Development Solutions
• Scientific Journal: Challenges Associated with Schedule I Therapeutic Development
• Webinar: Practical Approaches to Conducting Early Clinical Trials with Psychedelics